We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Matthew W. Coryell is the likely recipient of the following grants.
Years |
Recipients |
Code |
Title / Keywords |
Matching score |
2006 — 2007 |
Coryell, Matthew W |
F31Activity Code Description: To provide predoctoral individuals with supervised research training in specified health and health-related areas leading toward the research degree (e.g., Ph.D.). |
Fear-Related Effects of Disrupting Asic1a in Amygdala
[unreadable] DESCRIPTION (provided by applicant): Anxiety disorders cause considerable emotional distress and are frequently disabling, yet current therapies are inadequate. Understanding the molecular mechanisms underlying these disorders will be key in finding improved treatment. The Acid sensing ion channel 1 (ASIC1a) is a novel regulator of anxiety-like recently discovered in mice. The ASIC1a gene dose was found to significantly affect Pavlovian fear conditioning, an important animal model of anxiety. This finding suggests the hypothesis that ASIC1a plays a role in amygdala-dependent learning and memory. This hypothesis will be tested with the following aims: 1) Does pharmacologic inhibition of ASIC1a disrupt fear related learning or the expression of fear? 2) Does genetic disruption of ASIC1a restricted to the amygdala block normal fear related behavior? The proposed approach of combining pharmacologic and genetic strategies to target ASIC1a will provide the first steps for manipulating ASIC1a function in vivo. This will clarify its role in anxiety related behavior and could further elevate ASIC1a as a potential target for treatment of anxiety disorders in humans. [unreadable] [unreadable] [unreadable]
|
1 |